The Journal of Clinical Endocrinology & Metabolism· 2026Q1
Association between worsening time in range and microvascular complications in type 1 diabetes: real-world 5-year study
- 1citations
- Q1SCImago
- 2026year
Short summary
A 5-year study of 246 adults with type 1 diabetes found that a decrease in time in range (TIR) of 10% or more was associated with a 33.3% rate of microvascular complications, compared to 7.9% for stable TIR and 15.0% for increased TIR.
AI-generated from the title and abstract; the full text is not read.
Key points
- A 10% or greater decrease in time in range (TIR) over 5 years was associated with a 33.3% incidence of microvascular complications in type 1 diabetes.
- Stable or increased TIR showed significantly lower complication rates (7.9% and 15.0%, respectively).
- Continuous glucose monitoring (CGM)-derived metrics, particularly change in TIR (ΔTIR), were independently associated with outcomes after adjusting for baseline values and age.
- Models incorporating CGM metrics and age showed good discriminative performance (AUCs 0.757-0.787) for predicting complications.
AI-generated from the title and abstract; the full text is not read.
Abstract
CONTEXT: Beyond HbA1c, continuous glucose monitoring (CGM) is now widely used in clinical practice, providing more detailed information about glycemic control. However, its ability to predict long-term microvascular outcomes in type 1 diabetes remains unclear. OBJECTIVE: To evaluate the association between CGM-derived glucometrics and the 5-year incidence of microvascular complications, providing longitudinal real-world evidence in adults with type 1 diabetes. DESIGN: Longitudinal real-world cohort study with five-year follow-up. SETTING: Tertiary referral center. PARTICIPANTS: 246 adults with type 1 diabetes (median age 40 [28-53] years, diabetes duration 24 [13-33] years). INTERVENTION: No interventional treatment. MAIN OUTCOME MEASURE: Composite microvascular endpoint including nephropathy (persistent albuminuria ≥20 µg/min, eGFR <60 mL/min/1.73 m2, and/or RAAS inhibitor use for albuminuria), severe retinopathy (proliferative retinopathy, maculopathy, and/or blindness), and peripheral neuropathy (monofilament score <6/6 and/or abnormal nerve conduction). RESULTS: HbA1c decreased from 7.6% (59 mmol/mol) to 7.2% (55 mmol/mol), and time in range (TIR, 70-180 mg/dL) increased from 50 ± 14% to 61 ± 15%. All CGM-derived metrics (TIR, mean glucose, glucose management indicator) were associated with the composite endpoint. In this longitudinal real-world cohort, a ≥ 10% decrease in TIR was associated with higher complication rates (33.3%) compared with a stable TIR (7.9%) or ≥10% increase (15.0%) (p = 0.011). In multivariable analyses adjusted for age and baseline TIR, change in TIR (ΔTIR) remained independently associated with outcomes. BMI and systolic blood pressure were not significant. Models incorporating glucometrics and age showed acceptable discriminative performance (AUCs 0.757-0.787). CONCLUSIONS: CGM-derived glucometrics were associated with the 5-year incidence of microvascular complications in this real-world cohort, with ΔTIR potentially providing additional prognostic information beyond HbA1c. Further validation is needed before routine clinical implementation.
The authors' abstract, as published at the source. The Journal of Clinical Endocrinology & Metabolism, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine